Journal of Stem Cells Research Development & Therapy, 2018, 4: 011
Autologous Stromal Vascular Fraction: A New Era of Personal Cell Therapy
The fascinating story of Stromal Vascular Fraction (SVF) and its prominent role in autologous regenerative therapies (or Personal Cell Therapy – PCT) continues to evolve as scientific and regulatory issues develop. The primary objective of this special report will elucidate the history, composition and scientific analysis of SVF as an autologous biologic experiencing widespread clinical use. SVF has several distinct features that prevent it from ever being manufactured as a mass produced pharmaceutical and distributed for clinical use. Autologous SVF contains a unique mixture of 4 different types of autologous stem cells in an extremely rich cytokine milieu. It is intended to be used fresh and at point of care obviating its use in commercialization. It is personalized with the patient’s own DNA, and it contains the patient’s own biologic profile of possible measurable or unmeasurable communicable diseases. Other stem cell products being developed as drugs under research and development differ from autologous SVF as they generally contain doses of a single cell types that may or may not be autologous. Personal Cell Therapy using autologous biologic products should be protected from overbearing regulation with its use supported by clinical trials helping us to learn more about its regenerative potential. Laboratory investigations can then optimally help optimize areas that need further support.
To read the full article, click here DOI:10.24966/SRDT-2060/100011
Related: Autologous Stromal Vascular Fraction; Hematopoietic stem cells; Mesenchymal stem cells; Stem cell therapy; Stromal vascular fraction